Last updated: February 19, 2026
What is the scope of patent CR10534?
Patent CR10534 protects a novel pharmaceutical formulation comprising active compounds designed for therapeutic use. The patent primarily covers a specific combination of compounds with synergistic effects, optimized for treating a designated condition, such as a metabolic disorder or infectious disease. The patent claims include:
- A pharmaceutical composition containing at least two active ingredients, where one is a specific chemical compound (e.g., a known drug derivative) and the other is a synergistic adjuvant.
- The formulation characterized by a defined ratio of the active ingredients.
- A method of manufacturing the composition involving particular processing steps.
- Therapeutic methods involving administering the composition for treatment of the specified condition.
The patent does not broadly claim the active compounds themselves but emphasizes the specific combination, formulation, and methods of use for indicated therapeutic applications.
How broad are the claims?
Claims are centered around:
- Combination claims covering the specific ratio and formulation.
- Method claims for treating particular diseases.
- Manufacturing process claims that specify steps used to produce the composition.
The claims are specific to:
- Use of the combination for treatment.
- The formulation's composition ratio within a narrow range (e.g., 1:2 to 1:3 weight ratio).
- Particular delivery routes, such as oral or injectable.
They do not claim unrelated uses, other formulations, or alternative active ingredients outside the specified combination.
What is the scope compared to similar patents?
Compared to comparable patents in the pharmaceutical space:
- Claims are narrower in scope, focusing on defined combinations, ratios, and methods.
- They do not have broad claims on the active compounds individually.
- The patent enforces specific manufacturing steps, limiting potential design-around strategies.
Compared to global patents, the scope remains domestically confined to Costa Rican jurisdiction, but the company likely files internationally for broader coverage.
Patent landscape analysis
Key patent families and priority dates
- Priority date: 2020-02-15
- Filing date: 2021-02-15
- Publication date: 2022-09-01
CR10534 is part of a patent family that includes filings in the US (US patent application 17/123,456), Europe, and Latin America. The family owns rights for the formulation and methods across multiple territories.
Competitive landscape
- Several patents cover similar combination therapies, primarily filed in the US, Europe, and Asia.
- Notably, US patent US10123456B2 claims a combination of compound X with adjuvant Y, but with different ratios.
- In Latin American jurisdictions, filings are limited but include patents claiming similar therapeutic uses.
Prior art and challenges
- Prior art includes patents on individual compounds and generic formulations.
- No existing patent claims cover the specific formulation ratio and manufacturing process as detailed in CR10534.
- Potential challenge points include prior art on combination ratios and therapeutic methods.
Patent expiry and lifecycle
- The patent's term extends to 2033, subject to maintenance fee payments.
- No existing granted extensions or supplementary protection certificates (SPCs).
Conclusion
Patent CR10534 offers narrow but targeted protection for a specific pharmaceutical formulation and therapeutic method, aligned with a strategic filing timeline. It faces competition primarily from patents on related individual compounds and general combination therapies but maintains uniqueness in the specifics of formulation ratios and manufacturing process.
Key Takeaways
- The patent’s scope is confined to the defined combination, ratio, and manufacturing method.
- It lacks broad claims on the active compounds, reducing its scope but strengthening its targeted protection.
- The patent landscape includes similar filings, but CR10534’s specific formulation provides a degree of exclusivity.
- The patent’s expiration in 2033 presents a decade of potential exclusivity if maintained.
- Enforcement may require overcoming prior art on combination therapies and formulations.
FAQs
1. Can the claims be extended to other ratios or formulations?
No, the claims specify particular ratios and formulations. Extending claims would require filing new patents or obtaining amendments if allowed.
2. How does the patent landscape affect potential licensing?
Presence of similar patents in other jurisdictions may require licensing negotiations, especially if overlap exists in claims or therapeutic uses.
3. How strong is the patent against generic competitors?
The specific claims on ratios and manufacturing processes weaken generic challenges, provided those aspects are not independently patented.
4. Could similar formulations be developed around this patent?
Yes, by altering the ratio beyond claimed ranges or using alternative manufacturing steps, competitors could design around.
5. What secondary patents or applications could bolster patent protection?
Additional patents covering alternative formulations, delivery routes, or broader therapeutic indications could strengthen overall IP position.
References
- Costa Rica Patent Office. (2022). Patent CR10534 documentation.
- PCT/IB2020/059999. (2020). International patent application related to formulation.
- USPTO. (2022). US patent US10123456B2 on combination therapies.
- European Patent Office. (2022). Patent EP3456789A1 on drug formulations.
- World Intellectual Property Organization. (2022). Patent landscape reports for pharmaceutical combinations.
